Dendreon Gets An Rx
Comments: 0 - Date: May 31st, 2007 - Categories: Uncategorized
"The FDA indicated that either a positive interim or final analysis of survival...would address their request for the submission of additional clinical data in support of our efficacy claim"
Don't count Dendreon out just yet. The young biotech firm, which has weathered a roller-coaster ride since its prostate cancer drug, Provenge, was recommended by a Food and Drug Administration advisory panel- ... via Forbes.com